ASH 2023 | The potential of BGB-16673, a BTK degrader, for the treatment of R/R B-cell malignancies
Constantine Tam, MBBS (Hons), MD, FRACP, FRCPA, Alfred Hospital and Monash University, Melbourne, Australia, discusses a Phase I first-in-human study (NCT05006716) of the BTK degrader BGB-16673 in patients with relapsed/refractory (R/R) B-cell malignancies. Dr Tam highlights the ability of this drug to overcome BTK resistance in patients by degrading the BTK protein and emphasizes its great potential for improving the outcomes of patients who have stopped responding to prior BTK inhibitor treatment. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria: AbbVie, Janssen, BeiGene, LOXO, Novartis, Roche
Research Funding: AbbVie, Janssen, BeiGene
